Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 5032Carcinoma, Renal Cell 1579Urinary Bladder Neoplasms 1281Kidney Neoplasms 725Breast Neoplasms 644Neoplasms 633Carcinoma, Transitional Cell 493Carcinoma, Non-Small-Cell Lung 470Neoplasm Metastasis 469Melanoma 423Ovarian Neoplasms 403Colorectal Neoplasms 375Lung Neoplasms 334Pancreatic Neoplasms 263Sarcoma 233Stomach Neoplasms 227Uterine Cervical Neoplasms 226Testicular Neoplasms 216Non-Muscle Invasive Bladder Neoplasms 216Head and Neck Neoplasms 193Squamous Cell Carcinoma of Head and Neck 189Carcinoma, Hepatocellular 170Endometrial Neoplasms 167Colonic Neoplasms 167Esophageal Neoplasms 165Wilms Tumor 159Recurrence 131Triple Negative Breast Neoplasms 130Small Cell Lung Carcinoma 127Neuroblastoma 127

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Kidney Cancer × Genitourinary × Clear all
NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

British Columbia Cancer Agency

Phase 3 Not yet recruiting
142 enrolled
Genitourinary

Advanced Kidney Cancer

NCT05485883 2022-08-08

TILUR

Tianjin Medical University Second Hospital

Phase 2 Unknown
20 enrolled
Genitourinary

Advanced Kidney Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡